Literature DB >> 20335374

Inhibition of rat gut reperfusion injury with an agent developed for the mouse. Evidence that amplification of injury by innate immunity is conserved between two animal species.

Jalil Afnan1, Cyrus Ahmadi-Yazdi, Eric G Sheu, Sean M Oakes, Francis D Moore.   

Abstract

Murine reperfusion injury follows binding of specific IgM natural antibodies to neo-antigens exposed in ischemic tissue. Peptides that mimic the site of antibody binding in the injury prevent IgM binding when administered intravenously before reperfusion. To determine whether this pathogenic sequence is restricted to mice, we have tested the ability of the peptide to prevent reperfusion injury in a dissimilar species, the rat. Sprague-Dawley rats were subjected to 40 min of mesenteric ischemia followed by 180 min of reperfusion. The peptide mimic was administered intravenously prior to reperfusion. Gut injury was quantified using a scoring system based on the hematoxylin-and-eosin section. (125)I-labeled albumin was used to assess local (gut) and remote (lung) injury. The macroscopic appearance of bowel from peptide-treated animals was less edematous and hemorrhagic. Microscopic analysis showed a significantly reduced injury score in peptide-treated animals. Permeability data indicated a significant reduction in local and remote injury in peptide-treated animals. The data demonstrate attenuation of rat gut microvillus injury, of gut edema, and of remote injury following mesenteric ischemia-reperfusion due to administration of an intravenous peptide mimic of a murine ischemia neo-antigen, indicating a second species uses a similar ischemia neo-antigen and corresponding natural antibody specificity to amplify reperfusion injury to the point of necrosis. This mechanism of inflammation is potentially applicable to higher species.

Entities:  

Mesh:

Year:  2010        PMID: 20335374      PMCID: PMC2886695          DOI: 10.1152/ajpregu.00380.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  18 in total

1.  Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury.

Authors:  Ming Zhang; William G Austen; Isaac Chiu; Elisabeth M Alicot; Rachel Hung; Minghe Ma; Nicola Verna; Min Xu; Herbert B Hechtman; Francis D Moore; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

2.  Molecular phylogeny and divergence time estimates for major rodent groups: evidence from multiple genes.

Authors:  R M Adkins; E L Gelke; D Rowe; R L Honeycutt
Journal:  Mol Biol Evol       Date:  2001-05       Impact factor: 16.240

3.  Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle.

Authors:  J Pablo Abonia; Daniel S Friend; William G Austen; Francis D Moore; Michael C Carroll; Rodney Chan; Jalil Afnan; Alison Humbles; Craig Gerard; Pamela Knight; Yoshihide Kanaoka; Shinsuke Yasuda; Nasa Morokawa; K Frank Austen; Richard L Stevens; Michael F Gurish
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

4.  Functional activity of natural antibody is altered in Cr2-deficient mice.

Authors:  Russell R Reid; Sean Woodcock; Alexander Shimabukuro-Vornhagen; William G Austen; Lester Kobzik; Ming Zhang; Herbert B Hechtman; Francis D Moore; Michael C Carroll
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

5.  Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q.

Authors:  Melanie L Hart; Kathleen A Ceonzo; Lisa A Shaffer; Kazue Takahashi; Russell P Rother; Wende R Reenstra; Jon A Buras; Gregory L Stahl
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

6.  Intestinal reperfusion injury is mediated by IgM and complement.

Authors:  J P Williams; T T Pechet; M R Weiser; R Reid; L Kobzik; F D Moore; M C Carroll; H B Hechtman
Journal:  J Appl Physiol (1985)       Date:  1999-03

7.  Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.

Authors:  J Hill; T F Lindsay; F Ortiz; C G Yeh; H B Hechtman; F D Moore
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

8.  Placental mammal diversification and the Cretaceous-Tertiary boundary.

Authors:  Mark S Springer; William J Murphy; Eduardo Eizirik; Stephen J O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

9.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

Authors:  H F Weisman; T Bartow; M K Leppo; H C Marsh; G R Carson; M F Concino; M P Boyle; K H Roux; M L Weisfeldt; D T Fearon
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

10.  Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement.

Authors:  M R Weiser; J P Williams; F D Moore; L Kobzik; M Ma; H B Hechtman; M C Carroll
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  4 in total

1.  Prevention of intestinal ischemia-reperfusion injury in humanized mice.

Authors:  Eric G Sheu; Kohei Wakatsuki; Sean Oakes; Michael C Carroll; Francis D Moore
Journal:  Surgery       Date:  2016-04-15       Impact factor: 3.982

2.  Blockade of IgM-Mediated Inflammation Alters Wound Progression in a Swine Model of Partial-Thickness Burn.

Authors:  Hamed Sadeghipour; Radbeh Torabi; James Gottschall; Jorge Lujan-Hernandez; David H Sachs; Francis D Moore; Curtis L Cetrulo
Journal:  J Burn Care Res       Date:  2017 May/Jun       Impact factor: 1.845

Review 3.  State-of the-art review on the renal and visceral protection during open thoracoabdominal aortic aneurysm repair.

Authors:  Karl Waked; Marc Schepens
Journal:  J Vis Surg       Date:  2018-02-08

4.  Natural antibody - Biochemistry and functions.

Authors:  Ali Seyar Rahyab; Amit Alam; Aricka Kapoor; Ming Zhang
Journal:  Glob J Biochem       Date:  2011
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.